It appeared that pembrolizumab treatment alone induced upregulation of immune checkpoint in the tumor cells, contributing to becoming more resistant to T cell killing and evasion of the immune response via enhanced signaling through MET-STAT4-PD-L1 axis (33, 34). This evidence concerns the gene MET and neoplasm.